David Lebovitz
Stock Analyst at Citigroup
(4.03)
# 920
Out of 4,479 analysts
40
Total ratings
64.41%
Success rate
6.55%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $227 → $291 | $243.32 | +19.60% | 17 | Jun 25, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $34.16 | +11.24% | 1 | May 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $389 → $382 | $279.31 | +36.77% | 2 | May 8, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $94 → $91 | $82.13 | +10.80% | 1 | Apr 25, 2024 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $68 | $46.07 | +47.60% | 1 | Mar 6, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $31.17 | -45.46% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $109.18 | -15.74% | 3 | Feb 1, 2022 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | n/a | $47.11 | - | 2 | Mar 23, 2021 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | n/a | $42.67 | - | 2 | Mar 2, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | n/a | $4.30 | - | 1 | Feb 26, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | n/a | $6.52 | - | 3 | Feb 22, 2021 | |
| KPTI Karyopharm Therapeutics | Initiates: Overweight | n/a | $0.82 | - | 1 | Jul 2, 2020 | |
| ASND Ascendis Pharma | Maintains: Overweight | n/a | $133.98 | - | 1 | Apr 2, 2020 |
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $227 → $291
Current: $243.32
Upside: +19.60%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $34.16
Upside: +11.24%
Madrigal Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $389 → $382
Current: $279.31
Upside: +36.77%
BioMarin Pharmaceutical
Apr 25, 2024
Maintains: Neutral
Price Target: $94 → $91
Current: $82.13
Upside: +10.80%
Crinetics Pharmaceuticals
Mar 6, 2024
Initiates: Buy
Price Target: $68
Current: $46.07
Upside: +47.60%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $31.17
Upside: -45.46%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $109.18
Upside: -15.74%
Ionis Pharmaceuticals
Mar 23, 2021
Maintains: Underweight
Price Target: n/a
Current: $47.11
Upside: -
Rhythm Pharmaceuticals
Mar 2, 2021
Maintains: Overweight
Price Target: n/a
Current: $42.67
Upside: -
MacroGenics
Feb 26, 2021
Maintains: Underweight
Price Target: n/a
Current: $4.30
Upside: -
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $6.52
Upside: -
Karyopharm Therapeutics
Jul 2, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.82
Upside: -
Ascendis Pharma
Apr 2, 2020
Maintains: Overweight
Price Target: n/a
Current: $133.98
Upside: -